Abstract
A recurrent tumor in a young male demonstrates the progression of an ameloblastic fibroma to an ameloblastic sarcoma. Chemotherapy with Actinomycin D, Vincristine, and Cytoxan produced a complete response without evidence of recurrence 4 years after initiation of chemotherapy. The patient developed an aggressive malignant melanoma 1 year after all chemotherapy was discontinued.
MeSH terms
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
Cyclophosphamide / therapeutic use
-
Dactinomycin / therapeutic use
-
Drug Therapy, Combination
-
Head and Neck Neoplasms / complications
-
Humans
-
Jaw Neoplasms / drug therapy
-
Jaw Neoplasms / pathology*
-
Jaw Neoplasms / surgery
-
Male
-
Melanoma / complications
-
Neoplasm Recurrence, Local
-
Neoplasms, Multiple Primary
-
Odontogenic Tumors / drug therapy
-
Odontogenic Tumors / pathology*
-
Odontogenic Tumors / surgery
-
Vincristine / therapeutic use
Substances
-
Antineoplastic Agents
-
Dactinomycin
-
Vincristine
-
Cyclophosphamide